| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cell Growth & Differentiation |
Division of Experimental Medicine, Beth Israel-Deaconess Medical Center, Harvard Institutes of Medicine, Boston, Massachusetts 02115
The expression of vascular endothelial growth factor (VEGF) by breast tumors has been previously correlated with a poor prognosis in the pathogenesis of breast cancer. Furthermore, VEGF secretion is a prerequisite for tumor development. Although most of the effects of VEGF have been shown to be attributable to the stimulation of endothelial cells, we present evidence here that breast tumor cells are capable of responding to VEGF. We show that VEGF stimulation of T-47D breast cancer cells leads to changes in cellular signaling and invasion. VEGF increases the cellular invasion of T-47D breast cancer cells on Matrigel/fibronectin-coated transwell membranes by a factor of two. Northern analysis for the expression of the known VEGF receptors shows the presence of moderate levels of Flt-1 and low levels of Flk-1/KDR mRNAs in a variety of breast cancer cell lines. T-47D breast cancer cells bind 125I-labeled VEGF with a Kd of 13 x 10-9 M. VEGF induces the activation of the extracellular regulated kinases 1,2 as well as activation of phosphatidylinositol 3'-kinase, Akt, and Forkhead receptor L1. These findings in T-47D breast cancer cells strongly suggest an autocrine role for VEGF contributing to the tumorigenic phenotype.
This article has been cited by other articles:
![]() |
A. K. Lucio-Eterovic, Y. Piao, and J. F. de Groot Mediators of Glioblastoma Resistance and Invasion during Antivascular Endothelial Growth Factor Therapy Clin. Cancer Res., July 15, 2009; 15(14): 4589 - 4599. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. Aesoy, B. C. Sanchez, J. H. Norum, R. Lewensohn, K. Viktorsson, and B. Linderholm An Autocrine VEGF/VEGFR2 and p38 Signaling Loop Confers Resistance to 4-Hydroxytamoxifen in MCF-7 Breast Cancer Cells Mol. Cancer Res., October 1, 2008; 6(10): 1630 - 1638. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. G. Van den Eynden, M. Smid, S. J. Van Laere, C. G. Colpaert, I. Van der Auwera, T. X. Bich, P. van Dam, M. A. den Bakker, L. Y. Dirix, E. A. Van Marck, et al. Gene Expression Profiles Associated with the Presence of a Fibrotic Focus and the Growth Pattern in Lymph Node-Negative Breast Cancer Clin. Cancer Res., May 15, 2008; 14(10): 2944 - 2952. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. J. Burstein, A. D. Elias, H. S. Rugo, M. A. Cobleigh, A. C. Wolff, P. D. Eisenberg, M. Lehman, B. J. Adams, C. L. Bello, S. E. DePrimo, et al. Phase II Study of Sunitinib Malate, an Oral Multitargeted Tyrosine Kinase Inhibitor, in Patients With Metastatic Breast Cancer Previously Treated With an Anthracycline and a Taxane J. Clin. Oncol., April 10, 2008; 26(11): 1810 - 1816. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Salvador, B. Li, R. Hansen, D. E. Cramer, M. Kong, and J. Yan Yeast-Derived {beta}-Glucan Augments the Therapeutic Efficacy Mediated by Anti-Vascular Endothelial Growth Factor Monoclonal Antibody in Human Carcinoma Xenograft Models Clin. Cancer Res., February 15, 2008; 14(4): 1239 - 1247. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. J. Higgins, S. Liu, M. Abdelrahim, K. Vanderlaag, X. Liu, W. Porter, R. Metz, and S. Safe Vascular Endothelial Growth Factor Receptor-2 Expression Is Down-Regulated by 17{beta}-Estradiol in MCF-7 Breast Cancer Cells by Estrogen Receptor {alpha}/Sp Proteins Mol. Endocrinol., February 1, 2008; 22(2): 388 - 402. [Abstract] [Full Text] [PDF] |
||||
![]() |
M.-A. Herve, H. Buteau-Lozano, R. Vassy, I. Bieche, G. Velasco, M. Pla, G. Perret, S. Mourah, and M. Perrot-Applanat Overexpression of Vascular Endothelial Growth Factor 189 in Breast Cancer Cells Leads to Delayed Tumor Uptake with Dilated Intratumoral Vessels Am. J. Pathol., January 1, 2008; 172(1): 167 - 178. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. A. Burger, M. W. Sill, B. J. Monk, B. E. Greer, and J. I. Sorosky Phase II Trial of Bevacizumab in Persistent or Recurrent Epithelial Ovarian Cancer or Primary Peritoneal Cancer: A Gynecologic Oncology Group Study J. Clin. Oncol., November 20, 2007; 25(33): 5165 - 5171. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. L. Slongo, B. Molena, A. M. Brunati, M. Frasson, M. Gardiman, M. Carli, G. Perilongo, A. Rosolen, and M. Onisto Functional VEGF and VEGF receptors are expressed in human medulloblastomas Neuro-oncol, October 1, 2007; 9(4): 384 - 392. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. R. Emlet, K. A. Brown, D. L. Kociban, A. A. Pollice, C. A. Smith, B. B. L. Ong, and S. E. Shackney Response to trastuzumab, erlotinib, and bevacizumab, alone and in combination, is correlated with the level of human epidermal growth factor receptor-2 expression in human breast cancer cell lines Mol. Cancer Ther., October 1, 2007; 6(10): 2664 - 2674. [Abstract] [Full Text] [PDF] |
||||
![]() |
T.-M. Hong, Y.-L. Chen, Y.-Y. Wu, A. Yuan, Y.-C. Chao, Y.-C. Chung, M.-H. Wu, S.-C. Yang, S.-H. Pan, J.-Y. Shih, et al. Targeting Neuropilin 1 as an Antitumor Strategy in Lung Cancer Clin. Cancer Res., August 15, 2007; 13(16): 4759 - 4768. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. A. Burger Experience With Bevacizumab in the Management of Epithelial Ovarian Cancer J. Clin. Oncol., July 10, 2007; 25(20): 2902 - 2908. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. R. Hsu, W. Cai, A. Veeravagu, K. A. Mohamedali, K. Chen, S. Kim, H. Vogel, L. C. Hou, V. Tse, M. G. Rosenblum, et al. Multimodality Molecular Imaging of Glioblastoma Growth Inhibition with Vasculature-Targeting Fusion Toxin VEGF121/rGel J. Nucl. Med., March 1, 2007; 48(3): 445 - 454. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. Wang, H. Wang, Y. Guo, W. Ning, S. Katkuri, W. Wahli, B. Desvergne, S. K. Dey, and R. N. DuBois From the Cover: Crosstalk between peroxisome proliferator-activated receptor {delta} and VEGF stimulates cancer progression PNAS, December 12, 2006; 103(50): 19069 - 19074. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y. Wu, Z. Zhong, J. Huber, R. Bassi, B. Finnerty, E. Corcoran, H. Li, E. Navarro, P. Balderes, X. Jimenez, et al. Anti-vascular endothelial growth factor receptor-1 antagonist antibody as a therapeutic agent for cancer. Clin. Cancer Res., November 1, 2006; 12(21): 6573 - 6584. [Abstract] [Full Text] [PDF] |
||||
![]() |
S M Hyder Sex-steroid regulation of vascular endothelial growth factor in breast cancer. Endocr. Relat. Cancer, September 1, 2006; 13(3): 667 - 687. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Vacca, C. Scavelli, G. Serini, G. Di Pietro, T. Cirulli, F. Merchionne, D. Ribatti, F. Bussolino, D. Guidolin, G. Piaggio, et al. Loss of inhibitory semaphorin 3A (SEMA3A) autocrine loops in bone marrow endothelial cells of patients with multiple myeloma Blood, September 1, 2006; 108(5): 1661 - 1667. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. J. Higgins, S. Liu, M. Abdelrahim, K. Yoon, K. Vanderlaag, W. Porter, R. P. Metz, and S. Safe Vascular Endothelial Growth Factor Receptor-2 Expression Is Induced by 17{beta}-Estradiol in ZR-75 Breast Cancer Cells by Estrogen Receptor {alpha}/Sp Proteins Endocrinology, July 1, 2006; 147(7): 3285 - 3295. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. L. Mulkeen, T. Silva, P. S. Yoo, J. C. Schmitz, E. Uchio, E. Chu, and C. Cha Short Interfering RNA-Mediated Gene Silencing of Vascular Endothelial Growth Factor: Effects on Cellular Proliferation in Colon Cancer Cells Arch Surg, April 1, 2006; 141(4): 367 - 374. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. B. Wedam, J. A. Low, S. X. Yang, C. K. Chow, P. Choyke, D. Danforth, S. M. Hewitt, A. Berman, S. M. Steinberg, D. J. Liewehr, et al. Antiangiogenic and Antitumor Effects of Bevacizumab in Patients With Inflammatory and Locally Advanced Breast Cancer J. Clin. Oncol., February 10, 2006; 24(5): 769 - 777. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. J. Hicklin and L. M. Ellis Role of the Vascular Endothelial Growth Factor Pathway in Tumor Growth and Angiogenesis J. Clin. Oncol., February 10, 2005; 23(5): 1011 - 1027. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. C. O'Riain, D. J. Buggy, M. J. Kerin, R. W. G. Watson, and D. C. Moriarty Inhibition of the Stress Response to Breast Cancer Surgery by Regional Anesthesia and Analgesia Does Not Affect Vascular Endothelial Growth Factor and Prostaglandin E2 Anesth. Analg., January 1, 2005; 100(1): 244 - 249. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Wyckoff, W. Wang, E. Y. Lin, Y. Wang, F. Pixley, E. R. Stanley, T. Graf, J. W. Pollard, J. Segall, and J. Condeelis A Paracrine Loop between Tumor Cells and Macrophages Is Required for Tumor Cell Migration in Mammary Tumors Cancer Res., October 1, 2004; 64(19): 7022 - 7029. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Elkin, A. Orgel, and H. K. Kleinman An Angiogenic Switch in Breast Cancer Involves Estrogen and Soluble Vascular Endothelial Growth Factor Receptor 1 J Natl Cancer Inst, June 2, 2004; 96(11): 875 - 878. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. A. Parikh, F. Fan, W. B. Liu, S. A. Ahmad, O. Stoeltzing, N. Reinmuth, D. Bielenberg, C. D. Bucana, M. Klagsbrun, and L. M. Ellis Neuropilin-1 in Human Colon Cancer: Expression, Regulation, and Role in Induction of Angiogenesis Am. J. Pathol., June 1, 2004; 164(6): 2139 - 2151. [Abstract] [Full Text] [PDF] |
||||
![]() |
Q. Chen, S. Cai, K. G. Shadrach, G. D. Prestwich, and J. G. Hollyfield Spacrcan Binding to Hyaluronan and Other Glycosaminoglycans: MOLECULAR AND BIOCHEMICAL STUDIES J. Biol. Chem., May 28, 2004; 279(22): 23142 - 23150. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. L. Stephen, M. C. U. Gustafsson, M. Jarvis, R. Tatoud, B. R. Marshall, D. Knight, E. Ehrenborg, A. L. Harris, C. R. Wolf, and C. N. A. Palmer Activation of Peroxisome Proliferator-Activated Receptor {delta} Stimulates the Proliferation of Human Breast and Prostate Cancer Cell Lines Cancer Res., May 1, 2004; 64(9): 3162 - 3170. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. Ohuchida, K. Mizumoto, M. Murakami, L.-W. Qian, N. Sato, E. Nagai, K. Matsumoto, T. Nakamura, and M. Tanaka Radiation to Stromal Fibroblasts Increases Invasiveness of Pancreatic Cancer Cells through Tumor-Stromal Interactions Cancer Res., May 1, 2004; 64(9): 3215 - 3222. [Abstract] [Full Text] [PDF] |
||||
![]() |
S.-H. Tseng, S.-M. Lin, J.-C. Chen, Y.-H. Su, H.-Y. Huang, C.-K. Chen, P.-Y. Lin, and Y. Chen Resveratrol Suppresses the Angiogenesis and Tumor Growth of Gliomas in Rats Clin. Cancer Res., March 15, 2004; 10(6): 2190 - 2202. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. A. Masso-Welch, D. Zangani, C. Ip, M. M. Vaughan, S. F. Shoemaker, S. O. McGee, and M. M. Ip Isomers of Conjugated Linoleic Acid Differ in Their Effects on Angiogenesis and Survival of Mouse Mammary Adipose Vasculature J. Nutr., February 1, 2004; 134(2): 299 - 307. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y. Liu, L. H. Cheung, P. Thorpe, and M. G. Rosenblum Mechanistic studies of a novel human fusion toxin composed of vascular endothelial growth factor (VEGF)121 and the serine protease granzyme B: Directed apoptotic events in vascular endothelial cells Mol. Cancer Ther., October 1, 2003; 2(10): 949 - 959. [Abstract] [Full Text] |
||||
![]() |
E. Marshman, K. A. Green, D. J. Flint, A. White, C. H. Streuli, and M. Westwood Insulin-like growth factor binding protein 5 and apoptosis in mammary epithelial cells J. Cell Sci., February 15, 2003; 116(4): 675 - 682. [Abstract] [Full Text] [PDF] |
||||
![]() |
T.-H. Lee, H. K. Avraham, S. Jiang, and S. Avraham Vascular Endothelial Growth Factor Modulates the Transendothelial Migration of MDA-MB-231 Breast Cancer Cells through Regulation of Brain Microvascular Endothelial Cell Permeability J. Biol. Chem., February 7, 2003; 278(7): 5277 - 5284. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. E. Bachelder, M. A. Wendt, and A. M. Mercurio Vascular Endothelial Growth Factor Promotes Breast Carcinoma Invasion in an Autocrine Manner by Regulating the Chemokine Receptor CXCR4 Cancer Res., December 15, 2002; 62(24): 7203 - 7206. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y. Guo, A. P. Mazar, J.-J. Lebrun, and S. A. Rabbani An Antiangiogenic Urokinase-derived Peptide Combined with Tamoxifen Decreases Tumor Growth and Metastasis in a Syngeneic Model of Breast Cancer Cancer Res., August 15, 2002; 62(16): 4678 - 4684. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. A. Masso-Welch, D. Zangani, C. Ip, M. M. Vaughan, S. Shoemaker, R. A. Ramirez, and M. M. Ip Inhibition of Angiogenesis by the Cancer Chemopreventive Agent Conjugated Linoleic Acid Cancer Res., August 1, 2002; 62(15): 4383 - 4389. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. M. Veenendaal, H. Jin, S. Ran, L. Cheung, N. Navone, J. W. Marks, J. Waltenberger, P. Thorpe, and M. G. Rosenblum In vitro and in vivo studies of a VEGF121/rGelonin chimeric fusion toxin targeting the neovasculature of solid tumors PNAS, June 11, 2002; 99(12): 7866 - 7871. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cell Growth & Differentiation |